Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–14. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008;84(4):988–993. doi:10.1189/jlb.1107774.
   PubMed Web of Science ®Google Scholar
• Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–1326. doi:10.1016/j.cell.2009.11.025.
   PubMed Web of Science ®Google Scholar
• Hasim A, Abudula M, Aimiduo R, Ma J-Q, Jiao Z, Akula G, Wang T, Abudula A. Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One. 2012;7(9):e44952. doi:10.1371/journal.pone.0044952.
   PubMed Web of Science ®Google Scholar
• Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22(4):350–358. doi:10.1016/j.semcancer.2012.03.003.
   PubMed Web of Science ®Google Scholar
• Leone P, Shin E-C, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. JNCI Journal of the National Cancer Institute. 2013;105(16):1172–1187. doi:10.1093/jnci/djt184.
   PubMedGoogle Scholar
• Seliger B, Ferrone S, Class HLA I antigen processing machinery defects in cancer cells-frequency, functional significance, and clinical relevance with special emphasis on their role in T cell-based immunotherapy of malignant disease. Methods Mol Biol (Clifton, NJ). 2020;2055:325–350. doi:10.1007/978-1-4939-9773-2_15.
   PubMedGoogle Scholar
• Aptsiauri N, Ruiz-Cabello F, Garrido F. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses. Curr Opin Immunol. 2018;51:123–132. doi:10.1016/j.coi.2018.03.006.
   PubMed Web of Science ®Google Scholar
• Chang C-C, Pirozzi G, Wen S-H, Chung I-H, Chiu B-L, Errico S, Luongo M, Lombardi ML, Ferrone S. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 2015;290(44):26562–26575. doi:10.1074/jbc.M115.676130.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Ramsuran V, Rucevic M, Singh S, Lied A, Kulkarni V, O’hUigin C, Le Gall S, Carrington M. Posttranscriptional regulation of HLA-A protein expression by alternative polyadenylation signals involving the RNA-binding protein syncrip. The Journal of Immunology. 2017;199(11):3892–3899. doi:10.4049/jimmunol.1700697.
   PubMed Web of Science ®Google Scholar
• Eichmuller SB, Osen W, Mandelboim O, Seliger B. Immune modulatory microRNAs involved in tumor attack and tumor immune escape. JNCI. 2017;109(10). doi:10.1093/jnci/djx034.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.002.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/s0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Jiang C, Chen X, Alattar M, Wei J, Liu H. MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther. 2015;22(6):291–301. doi:10.1038/cgt.2015.19.
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Croce CM. MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol. 2014;15(9):445. doi:10.1186/s13059-014-0445-8.
   PubMed Web of Science ®Google Scholar
• Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis. 2012;33(10):1823–1832. doi:10.1093/carcin/bgs205.
   PubMed Web of Science ®Google Scholar
• Meyer S, Handke D, Mueller A, Meinhardt A, Jasinski-Bergner S, Mages S, Bukur J, Donia M, Straten P, Seliger B, et al. Role of signal transduction and microRNAs on the immunogenicity of melanoma cells. J Transl Med. 2015;13(Suppl 1):K15. doi:10.1186/1479-5876-13-s1-k15.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Jasinski-Bergner S, Lazaridou M-F, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, et al. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. CII. 2019;68(10):1689–1700. doi:10.1007/s00262-019-02373-1.
   Google Scholar
• Tsukerman P, Yamin R, Seidel E, Khawaled S, Schmiedel D, Bar-Mag T, Mandelboim O. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget. 2014;5(23):12141–12150. doi:10.18632/oncotarget.2559.
   PubMedGoogle Scholar
• Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature. 2011;472(7344):495–498. doi:10.1038/nature09914.
   PubMed Web of Science ®Google Scholar
• Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L, Solway J, Gern JE, Lemanske RF, Nicolae D, et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet. 2007;81(4):829–834. doi:10.1086/521200.
   PubMed Web of Science ®Google Scholar
• Zhu X-M, Han T, Wang X-H, Li Y-H, Yang H-G, Luo Y-N, Yin G-W, Yao Y-Q. Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet Gynecol. 2010;202(6):e591–e597. doi:10.1016/j.ajog.2010.03.002.
   Web of Science ®Google Scholar
• Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, Braun J, Wach S, Wullich B, Spath V, et al. Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget. 2016;7(18):26866–26878. doi:10.18632/oncotarget.8567.
   PubMedGoogle Scholar
• Friedrich M, Pracht K, Mashreghi M-F, Jäck H-M, Radbruch A, Seliger B. The role of the miR-148/-152 family in physiology and disease. Eur J Immunol. 2017;47(12):2026–2038. doi:10.1002/eji.201747132.
   PubMed Web of Science ®Google Scholar
• Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, Yagel S, Mandelboim O. MiRNA-mediated control of HLA-G expression and function. PLoS One. 2012;7(3):e33395. doi:10.1371/journal.pone.0033395.
   PubMed Web of Science ®Google Scholar
• Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, et al. microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients. Gastroenterology. 2018;155(3):784–798. doi:10.1053/j.gastro.2018.06.030.
   PubMed Web of Science ®Google Scholar
• Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, et al. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis. 2016;7(2):e2120. doi:10.1038/cddis.2016.28.
   PubMed Web of Science ®Google Scholar
• Bartoszewski R, Brewer JW, Rab A, Crossman DK, Bartoszewska S, Kapoor N, Fuller C, Collawn JF, Bebok Z. The unfolded protein response (UPR)-activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes. J Biol Chem. 2011;286(48):41862–41870. doi:10.1074/jbc.M111.304956.
   PubMed Web of Science ®Google Scholar
• Gao F, Zhao Z-L, Zhao W-T, Fan Q-R, Wang S-C, Li J, Zhang Y-Q, Shi J-W, Lin X-L, Yang S, et al. miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2013;431(3):610–616. doi:10.1016/j.bbrc.2012.12.097.
   PubMed Web of Science ®Google Scholar
• Pawelec G, Marsh SG. ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. CII. 2006;55(6):623–627. doi:10.1007/s00262-005-0117-3.
   Google Scholar
• Wulfanger J, Biehl K, Tetzner A, Wild P, Ikenberg K, Meyer S, Seliger B. Heterogeneous expression and functional relevance of the ubiquitin carboxyl-terminal hydrolase L1 in melanoma. Int J Cancer. 2013;133(11):2522–2532. doi:10.1002/ijc.28278.
   PubMed Web of Science ®Google Scholar
• Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R. Increased tumour cell PD -L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. JEADV. 2019;33(4):667–675. doi:10.1111/jdv.15302.
   Google Scholar
• Chen C, Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., Nguyen, J. T., Barbisin, M., Xu, N. L., Mahuvakar, V. R., Andersen, M. R. et al., Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179. doi: 10.1093/nar/gni178.
   PubMed Web of Science ®Google Scholar
• Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP. Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods. 2007;3(1):12. doi:10.1186/1746-4811-3-12.
   PubMed Web of Science ®Google Scholar
• Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem. 2010;285(40):30419–30426. doi:10.1074/jbc.M109.094284.
   PubMed Web of Science ®Google Scholar
• Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Müller A, Hiebl B, Holzhausen H-J, et al. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. MCR. 2013;11(11):1462–1477. doi:10.1158/1541-7786.mcr-13-0125.
   Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1–2):15–22. doi:10.1016/j.jim.2004.08.008.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Herrero S, Sordo-Bahamonde C, Gonzalez S, Lopez-Soto A. CD107a degranulation assay to evaluate immune cell antitumor activity. Methods Mol Biol (Clifton, NJ). 2019;1884:119–130. doi:10.1007/978-1-4939-8885-3_7.
   PubMedGoogle Scholar
• Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015;6(14):12297–12309. doi:10.18632/oncotarget.3655.
   PubMed Web of Science ®Google Scholar
• Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2007;36(Database):D149–D153. doi:10.1093/nar/gkm995.
   PubMed Web of Science ®Google Scholar
• Rehmsmeier M. Fast and effective prediction of microRNA/target duplexes. RNA (New York, NY). 2004;10(10):1507–1517. doi:10.1261/rna.5248604.
   PubMed Web of Science ®Google Scholar
• Lee JS, Ahn, Y. H., Won, H. S., Sun, S., Kim, Y. H., Ko, Y. H. Prognostic role of the microRNA-200 family in various carcinomas: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:1928021. doi:doi:10.1155/2017/1928021
   Google Scholar
• Senfter D, Madlener S, Krupitza G, Mader RM. The microRNA-200 family: still much to discover. Biomol Concepts. 2016;7(5–6):311–319. doi:10.1515/bmc-2016-0020.
   PubMedGoogle Scholar
• Xie K, Wang C, Qin N, Yang J, Zhu M, Dai J, Jin G, Shen H, Ma H, Hu Z, et al. Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk. Oncotarget. 2016;7(30):47966–47974. doi:10.18632/oncotarget.10299.
   PubMedGoogle Scholar
• Wang Y, Qiu C, Lu N, Liu Z, Jin C, Sun C, Bu H, Yu H, Dongol S, Kong B, et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner. Int J Oncol. 2018;52(6):2130–2142. doi:10.3892/ijo.2018.4359.
   PubMed Web of Science ®Google Scholar
• Zeng X, Qu X, Zhao C, Xu L, Hou K, Liu Y, Zhang N, Feng J, Shi S, Zhang L, et al. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling. The FASEB Journal. 2019;33(10):10717–10730. doi:10.1096/fj.201900273R.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang S, Li X, Jiang D, Yu H, Wu Q, Gao C, Wu Z. A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma. PLoS One. 2018;13(7):e0200290. doi:10.1371/journal.pone.0200290.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420–1435. doi:10.1158/2159-8290.cd-17-0593.
   PubMed Web of Science ®Google Scholar
• Maleno I, Aptsiauri N, Cabrera T, Gallego A, Paschen A, López-Nevot MA, Garrido F. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics. 2011;63(2):65–71. doi:10.1007/s00251-010-0494-4.
   PubMed Web of Science ®Google Scholar
• Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. CII. 2012;61(2):249–254. doi:10.1007/s00262-011-1153-9.
   Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342. doi:10.1126/scitranslmed.aar3342.
   PubMed Web of Science ®Google Scholar
• Cao J, Brouwer NJ, Jordanova ES, Marinkovic M, van Duinen SG, de Waard NE, Ksander BR, Mulder A, Claas FHJ, Heemskerk MHM, et al. HLA class I antigen expression in conjunctival melanoma is not associated with PD-L1/PD-1 status. Investigat ophthalmol Vis Sci. 2018;59(2):1005–1015. doi:10.1167/iovs.17-23209.
   PubMed Web of Science ®Google Scholar
• Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2012;131(2):387–395. doi:10.1002/ijc.26471.
   PubMed Web of Science ®Google Scholar
• Akbani R, Akdemir K, Aksoy B, Albert M, Ally A, Amin S, Arachchi H, Arora A, Auman J, Ayala B. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696. doi:10.1016/j.cell.2015.05.044.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A. et al. The immune landscape of cancer. Immunity. 2018;48:812–830.e814. doi: 10.1016/j.immuni.2018.03.023.
   Web of Science ®Google Scholar
• Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D. Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Rev Clin Immunol. 2016;12(8):879–893. doi:10.1080/1744666x.2016.1176529.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M. Identification of novel genes coding for small expressed RNAs. Science (New York, NY). 2001;294(5543):853–858. doi:10.1126/science.1064921.
   Google Scholar
• Bartel DP, Chen C-Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nature Reviews Genetics. 2004;5(5):396–400. doi:10.1038/nrg1328.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006;103(24):9136–9141. doi:10.1073/pnas.0508889103.
   PubMed Web of Science ®Google Scholar
• Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res. 2012;22(2):101–113. doi:10.1097/CMR.0b013e32834f6fbb.
   PubMed Web of Science ®Google Scholar
• Seliger B, Meinhardt A, Falke D. The role of immune modulatory microRNAs in tumors. INTEC. 2016. doi:10.5772/61805.
   Google Scholar
• Elson-Schwab I, Lorentzen A, Marshall CJ, Danen EHJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One. 2010;5(10):e13176. doi:10.1371/journal.pone.0013176.
   PubMed Web of Science ®Google Scholar
• Yang T, Cao C, Yang J, Liu T, Lei XG, Zhang Z, Xu S. miR-200a-5p regulates myocardial necroptosis induced by Se deficiency via targeting RNF11. Redox Biol. 2018;15:159–169. doi:10.1016/j.redox.2017.11.025.
   PubMed Web of Science ®Google Scholar
• Yang T, Liu T, Cao C, Xu S. miR-200a-5p augments cardiomyocyte hypertrophy induced by glucose metabolism disorder via the regulation of selenoproteins. J Cell Physiol. 2019;234(4):4095–4103. doi:10.1002/jcp.27206.
   PubMed Web of Science ®Google Scholar
• Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455(7209):64–71. doi:10.1038/nature07242.
   PubMed Web of Science ®Google Scholar
• Stavast CJ, Erkeland SJ. The non-canonical aspects of microRNAs: many roads to gene regulation. Cells. 2019;8(11):1465. doi:10.3390/cells8111465.
   PubMed Web of Science ®Google Scholar
• Seo J, Jin D, Choi C-H, Lee H, Unver T. Integration of microRNA, mRNA, and protein expression data for the identification of cancer-related microRNAs. PLoS One. 2017;12(1):e0168412. doi:10.1371/journal.pone.0168412.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11(11):860–872. doi:10.1038/nrd3864.
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63. doi:10.1038/nature07228.
   PubMed Web of Science ®Google Scholar